Does implantation of paclitaxel-eluting stents reduce angiographic evidence of restenosis and recurrent ischemia necessitating repeat revascularization procedures in patients with ST-segment elevation myocardial infarction undergoing primary PCI?
In patients with STEMI undergoing primary PCI, paclitaxel-eluting stents reduce restenosis and the need for repeat revascularization compared to bare-metal stents, without apparent safety concerns at 1 year.
In patients with ST-segment elevation myocardial infarction who were undergoing primary PCI, implantation of paclitaxel-eluting stents, as compared with bare-metal stents, significantly reduced angiographic evidence of restenosis and recurrent ischemia necessitating repeat revascularization procedures. No safety concerns were apparent at 1 year. (ClinicalTrials.gov number, NCT00433966.)
Stone et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: